Free Trial

Mackenzie Financial Corp Sells 462,783 Shares of Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company logo with Medical background

Mackenzie Financial Corp trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 68.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 213,879 shares of the medical instruments supplier's stock after selling 462,783 shares during the period. Mackenzie Financial Corp owned about 0.07% of Becton, Dickinson and Company worth $48,991,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company in the first quarter valued at $27,000. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company in the first quarter valued at $29,000. REAP Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Cornerstone Planning Group LLC grew its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares during the period. Finally, Nexus Investment Management ULC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $2.06 on Friday, reaching $176.19. 4,688,991 shares of the stock were exchanged, compared to its average volume of 2,814,753. The firm's 50 day moving average is $174.93 and its 200-day moving average is $200.87. The firm has a market cap of $50.50 billion, a PE ratio of 33.62, a P/E/G ratio of 1.35 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.17 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Raymond James Financial downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Finally, William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $219.22.

Read Our Latest Report on BDX

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines